Live feed
Vaxcyte, Inc. (NASDAQ: PCVX) announced the successful closing of its underwritten public offering, raising $632.5 million gross proceeds through the sale of 12,650,000 shares of co…
Read sourceVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, announced the pricing of an underwritten public offering of 11 million shares at $50 per share, generating $550 mill…
Read sourceVaxcyte announced progress on VAX-31, its 31-valent pneumococcal conjugate vaccine, with first participants dosed in the OPUS-2 Phase 3 adult trial evaluating concomitant administr…
Read sourceSubscription access
Ownership graphs, filings, risk signals, and full news archives are available in the workspace.
Ultimate owners, beneficial holders, and control chains.
LockedRevenue, margins, leverage, peer benchmarks, and KPIs.
LockedLatest filings, reports, and downloadable originals.
LockedSanctions, litigation signals, and risk scoring.
LockedExecutive roster, contacts, and org structure.
LockedSignals, subsidiaries, and related entities.
LockedTrack updates, receive alerts, and export verified reports across your company lists. Zero obligation.
Disclaimer: IndexBox Companies does not issue, announce, or publish this company profile. This information is aggregated from publicly available sources and is provided for informational purposes only.
